Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.11
MMSI's Cash-to-Debt is ranked lower than
91% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. MMSI: 0.11 )
Ranked among companies with meaningful Cash-to-Debt only.
MMSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.3 Max: No Debt
Current: 0.11
Equity-to-Asset 0.64
MMSI's Equity-to-Asset is ranked higher than
55% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. MMSI: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
MMSI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.69 Max: 0.85
Current: 0.64
0.44
0.85
Interest Coverage 3.22
MMSI's Interest Coverage is ranked lower than
90% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.64 vs. MMSI: 3.22 )
Ranked among companies with meaningful Interest Coverage only.
MMSI' s Interest Coverage Range Over the Past 10 Years
Min: 3.22  Med: 35.47 Max: 7656.67
Current: 3.22
3.22
7656.67
Piotroski F-Score: 8
Altman Z-Score: 4.32
Beneish M-Score: -2.31
WACC vs ROIC
8.31%
-72.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.15
MMSI's Operating Margin % is ranked higher than
51% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.03 vs. MMSI: 5.15 )
Ranked among companies with meaningful Operating Margin % only.
MMSI' s Operating Margin % Range Over the Past 10 Years
Min: 5.15  Med: 7.7 Max: 13.64
Current: 5.15
5.15
13.64
Net Margin % 4.80
MMSI's Net Margin % is ranked higher than
54% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.97 vs. MMSI: 4.80 )
Ranked among companies with meaningful Net Margin % only.
MMSI' s Net Margin % Range Over the Past 10 Years
Min: 3.33  Med: 4.76 Max: 9.13
Current: 4.8
3.33
9.13
ROE % 5.90
MMSI's ROE % is ranked higher than
50% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. MMSI: 5.90 )
Ranked among companies with meaningful ROE % only.
MMSI' s ROE % Range Over the Past 10 Years
Min: 4.17  Med: 5.47 Max: 11.56
Current: 5.9
4.17
11.56
ROA % 3.39
MMSI's ROA % is ranked higher than
53% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. MMSI: 3.39 )
Ranked among companies with meaningful ROA % only.
MMSI' s ROA % Range Over the Past 10 Years
Min: 2.31  Med: 3.66 Max: 9.59
Current: 3.39
2.31
9.59
ROC (Joel Greenblatt) % 10.77
MMSI's ROC (Joel Greenblatt) % is ranked lower than
52% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.60 vs. MMSI: 10.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MMSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.32  Med: 10.66 Max: 21.49
Current: 10.77
8.32
21.49
3-Year Revenue Growth Rate 8.70
MMSI's 3-Year Revenue Growth Rate is ranked higher than
67% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. MMSI: 8.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MMSI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 10.5 Max: 102.5
Current: 8.7
0.9
102.5
3-Year EBITDA Growth Rate 7.20
MMSI's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. MMSI: 7.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MMSI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.1  Med: 10.95 Max: 92
Current: 7.2
-9.1
92
3-Year EPS without NRI Growth Rate 4.90
MMSI's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. MMSI: 4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MMSI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -16.5  Med: 4.25 Max: 160.4
Current: 4.9
-16.5
160.4
GuruFocus has detected 5 Warning Signs with Merit Medical Systems Inc $MMSI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MMSI's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:TOPCF, NYSE:HYH, NAS:NXTM, NYSE:GKOS, NYSE:HAE, NAS:NVCR, NAS:ATRI, NAS:LMNX, NAS:OSUR, NAS:IRTC, NAS:PODD, OTCPK:ANSLF, NAS:ATRC, NAS:ANGO, NAS:MLAB, NAS:LMAT, NAS:PLSE, OTCPK:AMSJF, NAS:ATRS, OTCPK:GMDTF » details
Traded in other countries:MM3.Germany,
Headquarter Location:USA
Merit Medical Systems Inc designs, develops, manufactures and sells medical devices used in interventional and diagnostic procedures. Its products are used in thoracic surgery, interventional nephrology, vascular surgery, and oncology and pain management.

Merit Medical Systems Inc was organized in July 1987 as a Utah corporation. The Company designs, develops, manufactures and sells medical devices used in interventional and diagnostic procedures. It provides its products to physicians and healthcare professionals to enhance patient care and enable them to perform procedures safely and effectively. Its operations are divided into the following principal markets: diagnostic and interventional cardiology, interventional radiology, interventional gastroenterology, interventional pulmonology, vascular surgery, interventional nephrology, and thoracic surgery. Its devices include Rad Board, Rad Board Xtra, Rad Trac and Rad Rest, which are used for patient positioning during radial access procedures; Safeguard Pressure Assisted Device, which assists in obtaining and maintaining hemostasis after a femoral procedure, and the Air-Band Radial Compression Device, which is indicated to assist hemostasis of the radial artery puncture site while maintaining visibility. The Company's products are also used in other clinical areas such as thoracic surgery, interventional nephrology, vascular surgery, and oncology and pain management. The Company offers safety-related products and kits. Its ShortStop and ShortStop Advantage Temporary Sharps Holders address the potential safety issues associated with accidental needle sticks. Its extensive line of color-coded Medallion Syringes and the PAL Pen and Label Medication Labeling System comply with patient safety initiatives of The Joint Commission and are designed to help minimize mix-ups in administering medication. It also offers waste management products to help avoid accidental exposure to contaminated fluids such as Occupational Safety and Health Administration compliant waste disposal basins: the BackStop, BackStop+, MiniStop, MiniStop+, and DugOut. The Company offer devices used to gain and maintain vascular access while protecting the clinician from accidental cuts and needle sticks during procedures such as the Futura Safety Scalpel and angiography needles such as the Merit Advance and the SecureLoc Safety Introducer Needle. It also offers sheath introducers such as Prelude and mini access kits such as MAK and S-MAK, designed to provide clinicians with smooth, less traumatic, and convenient access to the patient's vasculature. The Company offers the Clo-Sur PLUS P.A.D, intended for the local management of bleeding wounds and the creation of a barrier to bacterial penetration. It also offers two independent, differentiated radial compression systems, the Finale Compression Device and the RADStat Radial Artery Compression Device. Its diagnostic guide wires are used to traverse vascular anatomy and aid in placing catheters and other devices such as the pre-coated InQwire Diagnostic Guide Wires. The Merit Laureate Hydrophilic Guide Wire promotes rapid catheter exchanges and minimizes friction. It also offers the BowTie Guide Wire Insertion Device, us

Top Ranked Articles about Merit Medical Systems Inc

Merit Medical’s Embosphere® Microspheres Receive FDA 513(f)(2) (de novo) Classification for Prostatic Artery Embolization Indication
Merit Medical Announces Appointment of New Director
Paul Tudor Jones’ Top 4 Health Care Buys Guru invested in multiple health care stocks in 1st quarter
Paul Tudor Jones (Trades, Portfolio)’ Tudor Investment Corp. gained 325 new holdings during the first quarter. Among his purchases were multiple health care stocks including VCA Inc. (NASDAQ:WOOF), DaVita Inc. (NYSE:DVA), Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) and Edwards Lifesciences Corp. (NYSE:EW). Read more...
Merit Medical to Participate at Three Conferences
Merit Medical Systems to Announce First Quarter Results on April 27, 2017
Merit Medical to Participate at Needham Healthcare Conference

SOUTH JORDAN, Utah, March 30, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it will present at the 16th Annual Needham Healthcare Conference being held April 4-5 at the Westin New York Grand Central Hotel.
On Wednesday, April 5, at 3:40 p.m. ET, Merit’s Chairman and Chief Executive Officer Fred P. Lampropoulos will give a presentation regarding Merit’s history, products, financial performance and prospects.  He will also participate in one-on-one meetings throughout the day. ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 280 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Tokyo, Japan; Singapore; and Melbourne, Australia.

Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167  e-mail: [email protected] Fax: (801) 253-1688

Read more...
Merit Medical Announces Closing of Public Offering of Common Stock
SOUTH JORDAN, Utah, March 29, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) (“Merit”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that it closed its previously announced underwritten public offering of 5,175,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $28.25 per share.  The net proceeds to Merit from the offering were approximately $136.5 million (after deducting underwriting discounts and estimated offering expenses payable by Merit).  Merit expects to use the net proceeds from the offering to repay debt under its existing long-term credit facility.
BofA Merrill Lynch and Piper Jaffray acted as joint book-running managers and representatives of the underwriters for the offering.  Wells Fargo Securities also acted as a joint book-running manager. Canaccord Genuity, Raymond James, and SunTrust Robinson Humphrey acted as co-managers.The offering was made pursuant to a registration statement on Form S-3 (333-193059) previously filed with, and subsequently declared effective by, the Securities and Exchange Commission. A final prospectus supplement relating to the offering was filed with the SEC and is available on its website (www.sec.gov).This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 280 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Tokyo, Japan; Singapore; and Melbourne, Australia.FORWARD-LOOKING STATEMENTS
           
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. Forward-looking statements in this release include statements regarding the public offering of shares of common stock and the anticipated use of the net proceeds therefrom, and are subject to a number of risks and uncertainties that may cause actual results or outcomes to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include risks and uncertainties that could affect Merit’s business and financial results described in the preliminary prospectus supplement and accompanying prospectus prepared in connection with the public offering, as well as Merit’s other filings with the SEC, including under the caption “Risk Factors” in Merit’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.  Forward-looking statements relate only to events as of the date on which the statements are made and actual results or events may differ materially from anticipated results or events. Except as required by law, Merit undertakes no obligation to update or revise any forward-looking statement, even if subsequent events cause its views to change.
Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167  e-mail: [email protected] Fax: (801) 253-1688

Read more...
Merit Medical Announces Full Exercise of Option to Purchase Additional Common Stock

SOUTH JORDAN, Utah, March 27, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) (“Merit”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 675,000 shares in full, bringing the total number of shares being sold in the public offering to 5,175,000 and the total expected net proceeds to $136.5 million (after deducting underwriting discounts and estimated offering expenses payable by Merit).  The offering is expected to close on or about March 28, 2017, subject to customary closing conditions.
Merit expects to use the net proceeds from the offering to repay debt under its existing credit facility. BofA Merrill Lynch and Piper Jaffray are acting as joint book-running managers and representatives of the underwriters for the offering.  Wells Fargo Securities is also acting as a joint book-running manager. Canaccord Genuity, Raymond James, and SunTrust Robinson Humphrey are acting as co-managers.
                       
Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, free of charge on the Securities and Exchange Commission’s website at www.sec.gov or by sending a request to (a) BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department (or by email at [email protected]) or (b) Piper Jaffray, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department (or by e-mail at [email protected] or telephone at (800) 747-3924. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities discussed herein will be offered and sold pursuant to an effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission, and the offering will be made only by means of a prospectus supplement and accompanying prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”). ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 280 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Tokyo, Japan; Singapore; and Melbourne, Australia. FORWARD-LOOKING STATEMENTS

This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. Forward-looking statements in this release include statements regarding the proposed public offering of shares of common stock and the anticipated use of the net proceeds therefrom, and are subject to a number of risks and uncertainties that may cause actual results or outcomes to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include risks relating to the sufficiency of demand for our common stock, the price we are able to obtain for our common stock and satisfaction of customary closing conditions for the offering for an underwritten offering of securities, as well as the risks and uncertainties that could affect Merit’s business and financial results described in the preliminary prospectus supplement and accompany prospectus referenced above, as well as Merit’s other filings with the SEC, including under the caption “Risk Factors” in Merit’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Forward-looking statements relate only to events as of the date on which the statements are made and actual results or events may differ materially from anticipated results or events. Except as required by law, Merit undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause its views to change.
Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167 e-mail: [email protected] Fax: (801) 253-1688

Read more...
Merit Medical Announces Pricing of Public Offering of Common Stock

SOUTH JORDAN, Utah, March 22, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) (“Merit”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced the pricing of its underwritten public offering of 4,500,000 shares of common stock at a price of $28.25 per share (before underwriting discounts).  In addition, Merit has granted the underwriters participating in the offering a 30-day option to buy up to an additional 675,000 shares of common stock at the public offering price, less underwriting discounts.  The offering is expected to close on or about March 28, 2017, subject to customary closing conditions.
Merit expects to use the net proceeds from the offering to repay debt under its existing credit facility. BofA Merrill Lynch and Piper Jaffray are acting as joint book-running managers and representatives of the underwriters for the offering.  Wells Fargo Securities is also acting as a joint book-running manager. Canaccord Genuity, Raymond James, and SunTrust Robinson Humphrey are acting as co-managers.
                       
Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, free of charge on the Securities and Exchange Commission’s website at www.sec.gov or by sending a request to (a) BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department (or by email at [email protected]) or (b) Piper Jaffray, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department (or by e-mail at [email protected] or telephone at (800) 747-3924. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities discussed herein will be offered and sold pursuant to an effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission, and the offering will be made only by means of a prospectus supplement and accompanying prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”). ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 280 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Tokyo, Japan; Singapore; and Melbourne, Australia. FORWARD-LOOKING STATEMENTS
           
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. Forward-looking statements in this release include statements regarding the proposed public offering of shares of common stock and the anticipated use of the net proceeds therefrom, and are subject to a number of risks and uncertainties that may cause actual results or outcomes to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include risks relating to the sufficiency of demand for our common stock, the price we are able to obtain for our common stock and satisfaction of customary closing conditions for the offering for an underwritten offering of securities, as well as the risks and uncertainties that could affect Merit’s business and financial results described in the preliminary prospectus supplement and accompany prospectus referenced above, as well as Merit’s other filings with the SEC, including under the caption “Risk Factors” in Merit’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Forward-looking statements relate only to events as of the date on which the statements are made and actual results or events may differ materially from anticipated results or events. Except as required by law, Merit undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause its views to change.
Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167 e-mail: [email protected] Fax: (801) 253-1688

Read more...
Merit Medical Announces Commencement of Public Offering of Common Stock

SOUTH JORDAN, Utah, March 20, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) (“Merit”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that it has commenced an underwritten public offering of shares of its common stock.  Merit expects to offer $125.0 million of shares of common stock and also plans to grant the underwriters participating in the offering a 30-day option to buy up to an additional $18.75 million of shares of common stock. The offering is subject to market conditions that make completion of the offering, and the size and terms thereof, uncertain. Merit expects to use the net proceeds from the offering to repay debt under its existing credit facility. BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers and representatives of the underwriters for the offering.  Wells Fargo Securities is also acting as a joint book-running manager.  Canaccord Genuity, Raymond James, and SunTrust Robinson Humphrey are acting as co-managers. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, free of charge on the Securities and Exchange Commission’s website at www.sec.gov or by sending a request to (a) BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department (or by email at [email protected]), or (b) Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department (or by e-mail at [email protected] or telephone at (800) 747-3924). This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities discussed herein will be offered and sold pursuant to an effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission, and the offering will be made only by means of a prospectus supplement and accompanying prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”). ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 280 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Tokyo, Japan; Singapore; and Melbourne, Australia. FORWARD-LOOKING STATEMENTS This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. Forward-looking statements in this release include statements regarding the proposed public offering of shares of common stock and the anticipated use of the net proceeds therefrom, and are subject to a number of risks and uncertainties that may cause actual results or outcomes to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include risks relating to the sufficiency of demand for our common stock, the price we are able to obtain for our common stock and satisfaction of customary closing conditions for the offering for an underwritten offering of securities, as well as the risks and uncertainties that could affect Merit’s business and financial results described in the preliminary prospectus supplement and accompany prospectus referenced above, as well as Merit’s other filings with the SEC, including under the caption “Risk Factors” in Merit’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Forward-looking statements relate only to events as of the date on which the statements are made and actual results or events may differ materially from anticipated results or events. Except as required by law, Merit undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause its views to change.
Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167 e-mail: [email protected] Fax: (801) 253-1688

Read more...

Ratios

vs
industry
vs
history
PE Ratio 55.35
MMSI's PE Ratio is ranked lower than
83% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.92 vs. MMSI: 55.35 )
Ranked among companies with meaningful PE Ratio only.
MMSI' s PE Ratio Range Over the Past 10 Years
Min: 12.91  Med: 29.65 Max: 66.08
Current: 55.35
12.91
66.08
Forward PE Ratio 33.11
MMSI's Forward PE Ratio is ranked lower than
64% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.95 vs. MMSI: 33.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 55.35
MMSI's PE Ratio without NRI is ranked lower than
82% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.92 vs. MMSI: 55.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
MMSI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.03  Med: 29.67 Max: 66.08
Current: 55.35
13.03
66.08
Price-to-Owner-Earnings 65.91
MMSI's Price-to-Owner-Earnings is ranked lower than
79% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.27 vs. MMSI: 65.91 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MMSI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.45  Med: 60.21 Max: 2796
Current: 65.91
22.45
2796
PB Ratio 2.52
MMSI's PB Ratio is ranked higher than
64% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. MMSI: 2.52 )
Ranked among companies with meaningful PB Ratio only.
MMSI' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.98 Max: 3.2
Current: 2.52
1.08
3.2
PS Ratio 2.61
MMSI's PS Ratio is ranked higher than
57% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. MMSI: 2.61 )
Ranked among companies with meaningful PS Ratio only.
MMSI' s PS Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.63 Max: 2.68
Current: 2.61
1.04
2.68
Price-to-Free-Cash-Flow 73.45
MMSI's Price-to-Free-Cash-Flow is ranked lower than
82% of the 71 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.79 vs. MMSI: 73.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MMSI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 21.9  Med: 47.23 Max: 189.92
Current: 73.45
21.9
189.92
Price-to-Operating-Cash-Flow 29.35
MMSI's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.17 vs. MMSI: 29.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MMSI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.22  Med: 14.62 Max: 29.65
Current: 29.35
9.22
29.65
EV-to-EBIT 45.73
MMSI's EV-to-EBIT is ranked lower than
86% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.84 vs. MMSI: 45.73 )
Ranked among companies with meaningful EV-to-EBIT only.
MMSI' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 22.7 Max: 49.9
Current: 45.73
8.1
49.9
EV-to-EBITDA 22.44
MMSI's EV-to-EBITDA is ranked lower than
61% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.46 vs. MMSI: 22.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
MMSI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 13.1 Max: 22.66
Current: 22.44
6.1
22.66
PEG Ratio 6.86
MMSI's PEG Ratio is ranked lower than
82% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. MMSI: 6.86 )
Ranked among companies with meaningful PEG Ratio only.
MMSI' s PEG Ratio Range Over the Past 10 Years
Min: 1.28  Med: 4.46 Max: 120.29
Current: 6.86
1.28
120.29
Shiller PE Ratio 64.89
MMSI's Shiller PE Ratio is ranked lower than
67% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.01 vs. MMSI: 64.89 )
Ranked among companies with meaningful Shiller PE Ratio only.
MMSI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.75  Med: 30.92 Max: 65.57
Current: 64.89
17.75
65.57
Current Ratio 2.59
MMSI's Current Ratio is ranked lower than
51% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. MMSI: 2.59 )
Ranked among companies with meaningful Current Ratio only.
MMSI' s Current Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.83 Max: 5.78
Current: 2.59
1.6
5.78
Quick Ratio 1.31
MMSI's Quick Ratio is ranked lower than
65% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.72 vs. MMSI: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
MMSI' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.42 Max: 3.56
Current: 1.31
0.77
3.56
Days Inventory 121.51
MMSI's Days Inventory is ranked higher than
54% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.19 vs. MMSI: 121.51 )
Ranked among companies with meaningful Days Inventory only.
MMSI' s Days Inventory Range Over the Past 10 Years
Min: 98.79  Med: 117.35 Max: 132.82
Current: 121.51
98.79
132.82
Days Sales Outstanding 54.59
MMSI's Days Sales Outstanding is ranked higher than
66% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.58 vs. MMSI: 54.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
MMSI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.18  Med: 47.04 Max: 54.59
Current: 54.59
41.18
54.59
Days Payable 33.45
MMSI's Days Payable is ranked lower than
74% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.98 vs. MMSI: 33.45 )
Ranked among companies with meaningful Days Payable only.
MMSI' s Days Payable Range Over the Past 10 Years
Min: 28.96  Med: 38.12 Max: 59.55
Current: 33.45
28.96
59.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.40
MMSI's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.30 vs. MMSI: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MMSI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -21.9  Med: -3.3 Max: -0.6
Current: -1.4
-21.9
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 7.41
MMSI's Price-to-Tangible-Book is ranked lower than
67% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.73 vs. MMSI: 7.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MMSI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.35  Med: 2.97 Max: 14.97
Current: 7.41
1.35
14.97
Price-to-Intrinsic-Value-Projected-FCF 3.18
MMSI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
66% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.26 vs. MMSI: 3.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MMSI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.55  Med: 2.44 Max: 128
Current: 3.18
1.55
128
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.17
MMSI's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
95% of the 22 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.16 vs. MMSI: 5.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.62
MMSI's Price-to-Median-PS-Value is ranked lower than
74% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. MMSI: 1.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MMSI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.04 Max: 5.76
Current: 1.62
0.3
5.76
Price-to-Peter-Lynch-Fair-Value 4.97
MMSI's Price-to-Peter-Lynch-Fair-Value is ranked lower than
73% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. MMSI: 4.97 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MMSI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.75  Med: 2.4 Max: 11.57
Current: 4.97
0.75
11.57
Price-to-Graham-Number 4.27
MMSI's Price-to-Graham-Number is ranked lower than
78% of the 96 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. MMSI: 4.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MMSI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.88  Med: 2.01 Max: 11.82
Current: 4.27
0.88
11.82
Earnings Yield (Greenblatt) % 2.20
MMSI's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. MMSI: 2.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MMSI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 4.4 Max: 12.4
Current: 2.2
2
12.4
Forward Rate of Return (Yacktman) % 11.47
MMSI's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.05 vs. MMSI: 11.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MMSI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.5  Med: 7.5 Max: 16.8
Current: 11.47
-2.5
16.8

More Statistics

Revenue (TTM) (Mil) $636.83
EPS (TTM) $ 0.67
Beta1.17
Short Percentage of Float3.54%
52-Week Range $18.22 - 37.65
Shares Outstanding (Mil)49.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 719 783 879
EPS ($) 1.11 1.31 1.48
EPS without NRI ($) 1.11 1.31 1.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for MMSI

Headlines

Articles On GuruFocus.com
180LA Wins Gold and Bronze Cannes Lions for Expedia and VisitBritain's "Visit Britain" Interactive F Jun 23 2017 
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in A Jun 23 2017 
Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis a Jun 23 2017 
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland Jun 23 2017 
Applied Ventures Ramps Investment in Korea with New Innovation Fund Jun 22 2017 
Evolent Health, Inc. Announces Pricing of Secondary Public Offering of Class A Common Stock Jun 22 2017 
SEACOR Marine Announces “Stalking Horse” Bid to Form Joint Venture With Montco Offshore, I Jun 22 2017 
Greenbrier announces webcast and conference call of quarterly financial results Jun 22 2017 
NXT Energy Solutions Announces Results of Annual General Meeting Jun 22 2017 
Motif Bio Announces Result of General Meeting and Total Voting Rights Jun 22 2017 

More From Other Websites
Merit Medical’s Embosphere® Microspheres Receive FDA 513(f)(2) (de novo) Classification for... Jun 22 2017
ETFs with exposure to Merit Medical Systems, Inc. : June 19, 2017 Jun 19 2017
Merit Medical Systems, Inc. :MMSI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Merit Medical Announces Appointment of New Director May 26 2017
Edited Transcript of MMSI earnings conference call or presentation 27-Apr-17 9:00pm GMT May 11 2017
Merit Medical to Participate at Three Conferences May 03 2017
Merit Medical beats 1Q profit forecasts Apr 27 2017
Merit Medical Reports Results for First Quarter of 2017 Apr 27 2017
Investor Network: Merit Medical Systems, Inc. to Host Earnings Call Apr 27 2017
Merit Medical Systems, Inc. – Value Analysis (NASDAQ:MMSI) : April 26, 2017 Apr 26 2017
Merit Medical Systems, Inc. breached its 50 day moving average in a Bullish Manner : MMSI-US : April... Apr 25 2017
[$$] Evercore ISI Sees 20% Upside in Salesforce.com Apr 07 2017
Merit Medical Systems, Inc. breached its 50 day moving average in a Bearish Manner : MMSI-US : April... Apr 05 2017
Merit Medical Systems to Announce First Quarter Results on April 27, 2017 Apr 04 2017
Top Ranked Momentum Stocks to Buy for March 30th Mar 30 2017
Merit Medical (MMSI) Closes 5.2M Follow-On Share Offering Mar 30 2017
Merit Medical to Participate at Needham Healthcare Conference Mar 30 2017
Merit Medical Announces Closing of Public Offering of Common Stock Mar 29 2017
Merit Medical Announces Full Exercise of Option to Purchase Additional Common Stock Mar 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}